Ultrasound real-time elastography can predict malignancy in BI-RADS-US 3 lesions by unknown
Wojcinski et al. BMC Cancer 2013, 13:159
http://www.biomedcentral.com/1471-2407/13/159RESEARCH ARTICLE Open AccessUltrasound real-time elastography can predict
malignancy in BI-RADSW-US 3 lesions
Sebastian Wojcinski1*, Esther Boehme2, André Farrokh2, Philipp Soergel1, Friedrich Degenhardt2
and Peter Hillemanns1Abstract
Background: Lesions of the breast that are classified BI-RADSW-US 3 by ultrasound are probably benign and
observation is recommended, although malignancy may occasionally occur.
In our study, we focus exclusively on BI-RADSW-US 3 lesions and hypothesize that sonoelastography as an adjunct
to conventional ultrasound can identify a high-risk-group and a low-risk-group within these patients.
Methods: A group of 177 breast lesions that were classified BI-RADSW-US 3 were additionally examined with
real-time sonoelastography. Elastograms were evaluated according to the Tsukuba Elasticity Score. Pretest and
posttest probability of disease (POD), sensitivity (SE), specificity (SP), positive (PPV) and negative predictive values
(NPV) and likelihood-ratios (LR) were calculated. Furthermore, we analyzed the false-negative and false-positive
cases and performed a model calculation to determine how elastography could affect the proceedings in
population screening.
Results: In our collection of BI-RADSW-US 3 cases there were 169 benign and eight malignant lesions. The pretest
POD was 4.5% (95% confidence interval (CI): 2.1–9.0). In patients with a suspicious elastogram (high-risk group), the
posttest POD was significantly higher (13.2%, p = 0.041) and the positive LR was 3.2 (95% CI: 1.7–5.9). With a benign
elastogram (low-risk group), the posttest POD decreased to 2.2%. SE, SP, PPV and NPV for sonoelastography in
BI-RADSW-US 3 lesions were 62.5% (95% CI: 25.9–89.8), 80.5% (95% CI: 73.5–86.0), 13.2% (95% CI: 5.0–28.9) and 97.8%
(95% CI: 93.3–99.4), respectively.
Conclusions: Sonoelastography yields additional diagnostic information in the evaluation of BI-RADSW-US 3 lesions
of the breast. The examiner can identify a low-risk group that can be vigilantly observed and a high-risk group that
should receive immediate biopsy due to an elevated breast cancer risk.
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More than one million women are newly diagnosed with
breast cancer each year [1]. Industrial nations with the
highest cancer rates include the U.S.A, Italy, Australia,
Germany, the Netherlands, Canada and France [2]. In
2000, the last year for which global data exists, approxi-
mately 400,000 women died from breast cancer, rep-
resenting 1.6 per cent of all female deaths [3]. The early
detection of breast cancer has moved into the very focus
of primary health care. There is sound evidence that the* Correspondence: s@wojcinski.de
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reproduction in any medium, provided the orrecent decline in cancer mortality observed in several
countries is due to early detection to a significant extent
[4]. The responsibility for this success includes improve-
ments in imaging technologies, but is also due to a
higher degree of health awareness and educational pro-
grams. Nevertheless, a significant number of false-
positive and false-negative findings still occur [5]. The
consequence of a false-positive result in diagnostic im-
aging is the performance of an unnecessary biopsy. A
false-negative result has an even more serious implica-
tion as the diagnosis of malignancy is delayed, with a po-
tentially worse clinical outcome for the patient. In order
to prevent excessive biopsies on the one hand and, in
particular, to guarantee the highest level of patient safetyal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tinuously refined.
Today, ultrasound (US) plays a decisive role in the diag-
nostic pathways, with high sensitivity and specificity [6].
Despite technical advances, the most important step in
bringing breast US to its current position was the intro-
duction of the standardized BI-RADSW-US-classification
system by the American College of Radiology (ACR) [7].
The ACR BI-RADSW–US lexicon provides various cat-
egories with predefined terminology to describe the dom-
inant features of breast lesions accurately. According to
the ACR, each lesion should be assigned a BI-RADSW-US
category ranging from BI-RADSW-US 0 to BI-RADSW-US
6 at the end of the diagnostic procedure [7]. The distinct
BI-RADSW-US classification also implies what further
clinical action should be taken: BI-RADSW-US 4 lesions
are possibly malignant and BI-RADSW-US 5 lesions are
probably malignant. Therefore, the appropriate conse-
quence is a biopsy, usually under US guidance. Malig-
nancy practically never occurs in BI-RADSW-US 2 lesions,
which are defined as benign findings.
To our understanding, the group of BI-RADSW-US 3
lesions remains a critical category. These findings are
probably benign and short-term follow-ups are recom-
mended. Nevertheless, malignancy is eventually diag-
nosed in about 3% of these lesions, resulting in a delayed
diagnosis of cancer in a considerable number of patients
[8]. Therefore, a suitable predictor for malignancy in
BI-RADS-W-US 3 lesions would be beneficial and of
clinical relevance.Figure 1 Tsukuba Elasticity Score (TES). Schematic view, sonoelastograp
or BGR-sign.Nowadays, newly developed US technologies may allow
a better differentiation of benign and malignant masses
[9]. The idea behind real-time tissue elastography
(sonoelastography) is that a region of interest is subjected
to a compression force (stress) and the resulting strain
(displacement) within the tissue is assessed [Figure 1]. The
most common way to apply stress is to compress the
tissue with the ultrasound probe (hand-held sonoelas-
tography). Another recently developed method is shear
wave elastography, which uses an acoustic push pulse to
induce an elastic shear wave that propagates through the
tissue. The velocity of the shear wave is measured by de-
tection pulses and provides a quantitative measurement of
tissue stiffness [10].
Our study was based on hand-held sonoelastography.
In a recent meta-analysis regarding all BI-RADSW-US
categories, this non-invasive ultrasound-based method
demonstrated a good sensitivity of 79% and an excellent
specificity of 88% compared to conventional B-mode US
(96% and 70%, respectively) [11]. Furthermore, when
sonoelastography is applied to a predefined group of
lesions, a diagnostic advantage may be achieved. This
has been demonstrated in a subgroup analysis of
BI-RADSW-US 3 lesions, where the probability of dis-
ease (POD) significantly increased from 8.3% to 45.5%
with a suspicious elastogram [6].
Therefore, we designed our prospective study to con-
centrate exclusively on BI-RADSW-US 3 lesions, and
scrutinize whether sonoelastography can truly filter out
malignancy in this group.hy and B-mode ultrasound of lesions categorized as TES 1–5
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high-risk group (prevalence of malignancy significantly
increased) and a low-risk group (prevalence of malig-
nancy significantly decreased) within the cohort of pa-
tients with a BI-RADSW-US 3 lesion (overall prevalence
of malignancy about 3%).
Methods
General design
Our study was carried out at the Breast Cancer Center
of Franziskus Hospital in Bielefeld, Germany. The study
cohort was selected from patients who were referred to
our clinic due to specific diagnostic queries. Patients
with a sonographically visible lesion categorized as
BI-RADSW-US 3 were regarded as being suitable for our
study. Patients with a current treatment of breast cancer,
skin disorders, inflammatory conditions of the breast,
current pregnancy or lactation or psychiatric problems
were excluded. Ultrasound examinations and sonoelas-
tography were not performed under study conditions but
for diagnostic purposes within the routine practice of our
breast cancer center. As we were using a standard of care
clinical protocol, the responsible ethics committee did not
require additional approval for the non-interventional de-
sign of our prospective case study (Hannover Medical
School, Ethics committee, Study-ID 1414–2012).
Ultrasound examinations
Ultrasound examinations were performed by the author
SW, a DEGUM (Deutsche Gesellschaft für Ultraschall in
der Medizin, German society for ultrasound in medi-
cine) level II certified senior consultant in gynecology
with 7 years’ experience in breast US [12]. For sonog-
raphy, two high-end ultrasound scanners were used:
1. The Siemens ACUSON S2000™ ultrasound system
(Siemens Medical Solutions, Inc., Mountain View,
CA, USA) equipped with the 18 L6 HD linear
transducer (5.5–18 MHz, 5.7 cm)
2. The Hitachi HI VISION AviusW ultrasound system
(Hitachi Medical Corporation, Inc., Tokyo, Japan)
equipped with the EUP L74M linear transducer
(5–13 MHz, 5.0 cm) or the EUP-L65 linear probe
(6–14 MHz, 3.8 cm)
One-hundred and fifty-three lesions were scanned
with the ACUSON S2000™ and 24 lesions were scanned
with the Hitachi HI VISION AviusW.
All patients received bilateral whole breast ultrasound.
B-mode pictures of the lesion were obtained and docu-
mented in two planes. As previously reported, the orien-
tation of the probe does not influence the elastographic
score [13]. Therefore, the elastograms were taken either
in the sagittal or horizontal orientation. In the mostcommon mode for sonoelastography, hard tissue appears
blue to turquoise and soft tissue appears red to green on
a continuous scale ranging from red through yellow,
green and turquoise to blue [Figures 1, 2, 3, 4 and 5].
According to the national regulating authority statutes,
breast US systems have to fulfill basic technical require-
ments and undergo regular quality control measures
[14]. These standards applied to the equipment used in
our study.
Following the ultrasound examination, further diag-
nostic steps (i.e. magnetic resonance imaging, mammog-
raphy, core needle biopsy, open biopsy or follow-up
examinations) were conducted whenever necessary. Fi-
nally, we used the following means to define the benign
or malignant nature of the lesions:
57 lesions (32.2%) were followed up after 6 months
and/or additionally examined by other imaging methods
and finally staged down to BI-RADSW 2 and conse-
quently categorized as certainly benign. In 120 cases
(67.8%) it was considered necessary to perform a fine
needle aspiration, an open biopsy or a core needle bi-
opsy at the time of the first consultation or during one
of the follow-up visits.
Image interpretation and data management
The elastograms were evaluated using the Tsukuba Elas-
ticity Score (TES), also known as the Itoh-Score or
Elasto-Score, which is a 5-point strain partly corre-
sponding to the BI-RADS classification [Figure 1]. The
cut-off point for malignancy is between TES 3 and TES
4 [15]. Therefore, lesions that are categorized as TES 1,
2 or 3 are considered probably benign, and lesions cate-
gorized as TES 4 and 5 are suspicious for cancer.
Due to technical reasons, liquid cysts are regularly as-
sociated with the BGR-sign (blue-green-red-sign, a color
pattern with blue in the top area of the lesion, green in
the middle and red at the bottom that particularly ap-
plies to the Hitachi system) or with a color distribution
resembling a “bull’s-eye” (which particularly applies to
the Siemens system). Lesions displaying these color
distributions are defined as probably benign, as this
phenomenon is regularly and exclusively observed in
cysts [16,17].
Statistics
MicrosoftW Office ExcelW 2003 (Microsoft Corporation)
was used for data collection.
Statistical analysis was performed using MedCalcW
11.6 statistical software (MedCalc Software bvba,
Belgium). In the primary analysis, we calculated the pre-
test probability of disease (POD) as well as the posttest
POD in the high-risk group (suspicious elastogram) and
in the low-risk group (benign elastogram). Pairwise com-
parisons were performed using the Z-test. Furthermore,
Figure 2 BI-RADSW-US 3 lesion with a suspicious elastogram, TES 4. The lesion was revealed to be malignant (true positive case).
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group) and the negative likelihood ratio (low-risk group).
If the lower boundary was greater than one for the high-
risk group and if the upper boundary was less than one
for the low-risk group the null hypotheses could be
rejected. Secondarily, we calculated sensitivity, specificity
and predictive values based on the Bayesian theorem.
For the calculation of 95% confidence levels we used
Newcombe intervals with continuity correction [18].
Normality was tested with the Agostino-Pearson-test.
The Student’s t-test was used for numerical data and
comparison of means when normality holds. For dis-Figure 3 BI-RADSW-US 3 lesion with a benign elastogram, TES 2. Thetributions far from normal, the Mann–Whitney U test
was used. Statistical significance was assumed at p < 0.05
for all tests.
Furthermore, we performed a model calculation to de-
termine how elastography could affect the proceedings
in population screening with a given prevalence of
BI-RADSW-US 3 lesions. For this purpose, we compared
data from the literature concerning the biopsy rate in
BI-RADSW-US 3 lesions with the estimated proportion
of BI-RADSW-US 3 lesions that would be biopsied
after an additional elastogram by simple percentage
calculation.lesion was revealed to be malignant (false negative case).
Figure 4 BI-RADSW-US 3 lesion with a benign elastogram, TES 2. The lesion was revealed to be benign (true negative case).
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Data were collected between June 2009 and April 2012.
The study patients had an average age of 48.0 ± 14.3 -
years, ranging from 16 to 79 years. In total, data from
177 BI-RADSW-US 3 lesions in 153 patients were col-
lected. The average diameter of the lesions was 14 ±
7 mm (range 4 to 46 mm). Finally, 169 lesions (95.5%)
were identified as benign and 8 lesions (4.5%, 95% CI:
2.1-9.0) were found to be malignant.Figure 5 BI-RADSW-US 3 lesion with a suspicious elastogram, TES 5. TPrimary analysis: probability of disease and likelihood
ratios
The pretest POD was 4.5% (95% CI: 2.1–9.0) and rose sig-
nificantly to 13.2% (95% CI: 5.0–28.9) with a suspicious
elastogram in the high-risk group (p = 0.041). With a be-
nign elastogram, the posttest POD decreased to 2.2% (95%
CI: 0.6–6.7) in the low-risk group (p = n.s.) [Table 1].
Accordingly, the negative likelihood ratio was 0.5 (95%
CI: 0.2–1.1). Therefore, the upper boundary for the low-he lesion was revealed to be benign (false positive case).
Table 1 Primary outcome analysis
Effect of sonoelastography on the probability of disease
TES 1–3 or BGR-sign (test negative,
benign elastogram, low-risk group)
TES 4–5 (test positive, suspicious
elastogram, high-risk group)
pretest POD 4.5% a, b (2.1-9.0)
posttest POD 2.2% b, c (0.6-6.7) 13.2% a, c (5.0-28.9)
Likelihood ratio 0.5 (0.2-1.1) 3.2 (1.7-5.9)
Comparison of pretest- and posttest-POD and likelihood ratios.
95% confidence interval in brackets.
POD = probability of disease; TES = Tsukuba elasticity score; BGR = blue-green-red.
a p = 0.041 (comparison of POD before test and POD after positive test).
b p = 0.268 (comparison of POD before test and POD after negative test).
c p = 0.004 (comparison of POD after negative test and POD after positive test).
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for this group the null hypothesis could not be rejected.
Moreover, for the high-risk group, the positive likeli-
hood ratio was 3.2 (95% CI: 1.7–5.9). In this group the
lower boundary was greater than one and, consequently,
we could reject the null hypothesis.Sensitivity, specificity, predictive values and prevalence of
malignancy
The sensitivity of the sonoelastography was 62.5% (95%
CI: 25.9–89.8), which means that sonoelastography
could recognize approximately two out of three malig-
nancies in the group of BI-RADSW-US 3 lesions. The
specificity was 80.5% (95% CI: 73.5–86.0), and the posi-
tive and negative predictive values were found to be
13.2% (95% CI: 5.0–28.9) and 97.8% (95% CI: 93.3–99.4),
respectively [Table 2].Table 3 Prevalence of malignant lesions within the
different elastography scoresDescriptive analysis of the malignant lesions
The prevalence of malignancy was 4.5% (95% CI: 2.1–
9.0) for the BI-RADSW-US 3 lesions in our study, as we
eventually detected eight breast cancer cases. Out of
these eight lesions, none was categorized TES 1, two le-
sions were categorized TES 2, one lesion was categorized
TES 3 and five lesions were correctly categorized TES 4
(n = 4) or TES 5 (n = 1) [Table 3].
The characteristics of the eight breast cancer cases are
shown in Table 4.Table 2 Sensitivity, specificity and predictive values for
sonoelastography in BI-RADSW-US 3 lesions
Sensitivity, specificity and predictive values for sonoelastography
Prevalence of malignancy in BI-RADSW-US 3 4.5% (2.1-9.0)
Sensitivity 62.5% (25.9-89.8)
Specificity 80.5% (73.5-86.0)
Positive predictive value 13.2% (5.0-28.9)
Negative predictive value 97.8% (93.3-99.4)
95% confidence intervals in brackets.Seven patients presented with a mammogram, but there
was only one patient with a suspicious mammogram
(BI-RADS 4) and one patient with a mammogram that
recommended additional imaging evaluation (BI-RADS 0).
The other breast cancer patients (n = 5) had benign or
probably benign mammograms (BI-RADS 2 or 3).
With eight patients, the breast cancer group is too
small to permit statistical comparison of true-positive
(suspicious elastogram) and false-negative (benign
elastogram) cases, but there was a tendency for smaller
lesions located deeper in the breast in the subgroup of
false-negative elastograms [Table 4]. Examples of a true-
positive and a false-negative breast cancer case are given
in Figures 2 and 3.
Analysis of the benign lesions
Focusing on the 169 benign lesions, 136 elastograms were
benign and 33 elastograms were suspicious. Therefore,
elastography showed a false-positive result in approxi-
mately one out of five benign BI-RADSW-US 3 lesions.
Comparing these true-negative and false-positive cases,
there was no difference regarding the size of the lesions or
their distance from the skin. Regarding age, women
with a suspicious elastogram (false-positive cases) were
significantly older than women with a benign elastogramPrevalence of malignancy according to the
Tsukuba Elasticity Score
TES n Prevalence of malignant lesions
1 7 0% (0.0-43.9)
2 82 2.4% (0.4-9.4)
3 46 2.2% (0.1-13.0)
4 29 13.8% (4.5-32.6)
5 9 11.1% (0.6-49.3)
BGR-sign 4 0% (0.0-60.4)
95% confidence interval in brackets. TES = Tsukuba elasticity score; BGR = blue-
green-red.
Table 4 Characteristics of the breast cancer patients in our study sorted by the results from the elastogram
(comparison of true positives and false negatives)
Characteristics of the breast cancer patients










True positive cases (suspicious elastogram in breast cancer patients)
77 IDC 21 17 5 4 3 0
73 IDC 15 22 5 4 3 14
77 DCIS 10 14 2 4 0 0
39 DCIS 5 12 6 4 n.a.1 n.a.1
58 IDC 12 12 6 5 2 12
False negative cases (benign elastogram in breast cancer patients)
71 IDC 8 8 12 2 4 0
48 IMC 8 9 4 2 2 0
71 IDC 11 12 18 3 3 0
US = ultrasound; TES = Tsukuba elasticity score; IDC = invasive ductal carcinoma; DCIS = ductal carcinoma in situ; IMC = invasive mucinous carcinoma;
MG =mammography; n.a. = not available.
1not available: The patient presented with a palpable lesion that was exclusively diagnosed with ultrasound as the patient was less than 40 years old.
Wojcinski et al. BMC Cancer 2013, 13:159 Page 7 of 11
http://www.biomedcentral.com/1471-2407/13/159(true-negative cases) (53.1 versus 45.9 years, p = 0.008)
[Table 5]. Examples of a true-negative and a false-positive
result are given in Figures 4 and 5.
Model calculation
Based on our findings, we performed a model calculation
to estimate how elastography could affect the proceedings
in screening populations. As demonstrated in the ACRIN
6666 trial, BI-RADSW-US 3 lesions occur in about 19.5%
of high-risk women and at least 16.6% of BI-RADSW-US 3
patients can be expected to be ultimately biopsied as the
lesions are upgraded in the follow-up examinations [19].
This means that about 3.2% of all screened women usually
need a biopsy due to a BI-RADSW-US 3 lesion. In our
study, 21.5% of BI-RADSW-US 3 lesions had a suspicious
elastogram and immediate biopsy was recommended.
Consequently, focusing on patients with BI-RADSW-US 3Table 5 Characteristics of women with benign lesions sorted
positives and false negatives)
Characteristics of women
True negative case
(benign elastogram in beni
N 136
Age (years; mean ± SD) 45.9 ± 14.0
Distance from skin in US (mm; mean ± SD) 6.6 ± 3.8
Longest axis in US (mm; mean ± SD) 13.7 ± 6.1
US-platform S: 84.6%
H: 15.4%
US = ultrasound; SD = standard deviation.
1 Student’s t-test.
2 Mann–Whitney U test.
3 Z-Test.lesions, the biopsy rate would increase from 16.6%
(management without elastography) to 21.5% (indica-
tion to biopsy based on the elastogram). Focusing on
the screening population, in which BI-RADSW-US 3 le-
sions only occur in about 20% of the women, the overall
biopsy rate of 3.2% (without elastography) would in-
crease to 4.2% (with elastography). However, this would
allow the detection of 62.5% of cancers directly during
the first consultation, instead of performing the biopsy
many months or even years later after the tumor pro-
gresses in the follow-up examinations.
Discussion
Diagnostic performance of sonoelastography in
BI-RADSW-US 3 lesions
Compared to mammography and conventional ultra-





(suspicious elastogram in benign lesions)
p
33
53.1 ± 10.7 0.0081
7.3 ± 3.3 n.s.
(0.158)2
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breast lesions [6]. Nevertheless, there are plenty of clin-
ical situations where such additional information is not
imperative. Patients almost never receive a single im-
aging technique alone (i.e. conventional ultrasound,
mammography or magnetic resonance imaging), but
usually undergo several different examinations before re-
ceiving a final diagnosis. Therefore, in a realistic setting,
sonoelastography is not applied as a single method but
is used in addition to other examinations in “heavily-
pre-diagnosed patients”.
An elastogram, for example, might be capable of iden-
tifying a breast lesion as highly suggestive of malignancy,
but if this lesion was already suspicious on the mammo-
gram (i.e. BI-RADSW 5) and/or in the conventional
ultrasound (i.e. BI-RADSW-US 5), this additional infor-
mation would not have an effect on the management of
the patient.
Therefore, we need to concentrate on patients and
breast lesions where the appropriate action is as yet
unclear and a more advanced assessment is needed. This
is the rationale for our focus on patients with BI-
RADSW-US 3 lesions. The risk for malignancy is rela-
tively low in this category, but can reach 3% or even
more in distinct patient populations [7,8,20]. In our
study, the prevalence of breast cancer was moderately
higher (4.5%), but the 95% CI (2.1-9.0) suggests that our
population shows an acceptable distribution of benign
and malignant cases and can be regarded as representative
for other populations. Sonoelastography demonstrated a
helpful discrimination of patients into a low-risk group
(posttest POD 2.2%) or a high-risk group with a signifi-
cantly increased posttest POD of 13.2%. In addition, most
of the breast cancer patients in our study had a benign or
probably benign mammogram (i.e. BI-RADSW 2 or 3).
Accordingly, further diagnostic steps were initially not in-
dicated and the elastogram alone led to the diagnosis of
cancer.
This is why we recommend the application of
sonoelastography to BI-RADSW-US 3 lesions. The deci-
sion of whether to take a histological specimen or
merely perform follow-up examinations in a patient can
then be based on the results from the elastogram.
Can we detect more cancers even as we reduce the
number of biopsies?
A missed cancer or a delayed diagnosis of cancer may
have a decisive impact on the survival of a patient.
Therefore, a perfectly arranged diagnostic setting is cru-
cial for our patients.
Although BI-RADSW-US 3 lesions are probably be-
nign, there is still a substantial risk of malignancy for the
individual patient. As demonstrated by our results,
sonoelastography has the power to identify a high-riskgroup with a three-fold increased risk of malignancy as
well as a low-risk group with a decreased risk of malig-
nancy. Nevertheless it has to be discussed whether this
procedure can be transferred into our daily clinical rou-
tine. When performing breast diagnostics, there are two
major aims: On the one hand, we intend to increase the
number of correctly and early identified breast cancers
(and consequently avoid missed malignancies and de-
layed diagnoses of cancer); on the other hand we try to
reduce the number of unnecessary biopsies. In fact, both
aims often behave reciprocally with each other. Never-
theless, our investigations should be aimed at developing
methods that have a significant effect on diagnostic
accuracy, but which only cause a slight increase in the
biopsy rate.
Concerning BI-RADSW-US 3 lesions, performing
short-term follow-up examinations has been suggested
[7]. However, at least 16.6% of these patients usually
need a biopsy during one of these follow-ups, as the
tumor progresses or changes its morphology [19]. Fur-
thermore, we experience an increase of biopsies in
BI-RADSW-US 3 lesions, as patients often demand a
histological confirmation rather than repeated examina-
tions. As a consequence, many patients with a BI-
RADSW-US 3 lesion are still biopsied today despite all of
the recommendations.
Based upon this experience, sonoelastography would
only slightly increase the number of biopsies if this
technology were to be used as an adjunct to conven-
tional ultrasound. We estimate that, in the group of BI-
RADSW-US 3 lesions, the biopsy rate would increase by
4.9% (from 16.6% to 21.5%), but as BI-RADSW-US 3 le-
sions only occur in every fifth woman, the overall biopsy
rate in the entire population would only rise by 1%.
What is more, two thirds of all cancers in this group
could be diagnosed immediately at the time of the first
examination. To our way of thinking, the relationship
between the only slightly increased biopsy rate and the
positive predictive value of sonoelastography is defin-
itely favorable. So far, elastography has not shown an
ability to decrease the biopsy rate, but patient safety
could be much higher with this technology.
Why does sonoelastography fail in some cancers?
In our study, five out of eight breast cancers were cor-
rectly classified as suspicious on the elastogram, but
there were also three false-negative results.
In 2006, Thomas et al. published data on 108 breast
tumor patients [21]. The authors concluded that there may
be limitations to sonoelastography for lesions that are
extensive, inhomogeneous, located deep in the breast or re-
lated to rare histological types [21]. In our study, false-
negative cases showed a tendency to be located deeper in
the breast, which matches the experiences of Thomas et al.
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method in 222 breast lesions and put forward the idea
that the accuracy of sonoelastography may be impaired
in mucinous carcinoma of the breast [22]. Interestingly,
our only case of a mucinous carcinoma also exhibited a
benign elastogram. Mucinous carcinomas show a char-
acteristic pattern of solid portions consisting of tumor
cells and relatively soft areas consisting of liquid mucus.
This growth pattern can be expected to have an effect
on the physical properties of the tumor, i.e. these tumors
can be expected to appear much softer on the elas-
togram than entirely solid tumors. This is further con-
sistent with the idea that the elastogram is impaired in
invasive mucinous carcinoma. Furthermore, Farrokh
et al. experienced that the accuracy of sonoelastography
decreased when the tumor diameter was larger than
20 mm [22].We have no data for this latter hypothesis,
as none of the tumors in our study was significantly lar-
ger than 20 mm.
Why does sonoelastography show suspicious results in
benign lesions?
Tissue stiffens as malignant tumors form and grow, but
this effect may be also observed in benign lesions.
Therefore, the positive predictive value of sonoelas-
tography remains low and there are a number of false-
positive results, especially in populations with a low
prevalence of malignity. Nevertheless, we identified one
major variable that was strongly associated with false-
positive elastograms. Women with a benign lesion and a
suspicious elastogram (false-positive group) were signifi-
cantly older than women with a benign lesion and a be-
nign elastogram (true-negative group). Our finding can
be explained by the fundamental principle of hand-held
sonoelastography: This technology allows an estimation
of the elasticity of the tissue by comparing different
structures within the region of interest before and after
applying stress. As a result, the mechanical properties of
the surrounding tissue have a decisive impact on the ap-
pearance of the lesion on the elastogram. Usually, benign
lesions appear soft on sonoelastography, but a benign le-
sion may also appear relatively hard if the adjacent tissue
is relatively soft. This model of an “elastographic con-
trast” has been described before [23]. Focusing on be-
nign lesions, this “elastographic contrast” seems to work
better in relatively hard (meaning dense) breast tissue.
Consequently, the correct classification of a benign le-
sion in a less dense breast seems to be more difficult
with sonoelastography. Finally, breast density is strongly
correlated with the patient’s age. As the breast tissue be-
comes less dense with age, the “elastographic contrast”
diminishes for benign lesions and the false-positive rate
rises, as demonstrated by our results. Hence, we support
the concept of an “elastographic contrast”.Implications of the Tsukuba elasticity score
The so-called Tsukuba Elasticity Score, which is com-
monly used for sonoelastography, has never been pro-
spectively validated in larger populations. Therefore, we
lack final data demonstrating that the performance char-
acteristics of the TES are suitable for the evaluation of
elastograms. Nevertheless, the TES illustrated reprodu-
cible results in multiple studies and a recent meta-
analysis [6,11,21]. The cut-off point to discriminate
benign and malignant lesions is established between TES
3 and 4. In our study, the risk for malignancy was actu-
ally low for TES 1, 2 and 3 (0%, 2.4% and 2.2%, respect-
ively) and considerably higher for TES 4 and 5 (13.8%
and 11.1%, respectively). Hence, we consider this grad-
ation as reliable. Nevertheless, up to 13% malignancy
has been reported for TES 3 lesions in some studies
[15]. Therefore, as long as the final validation of the
score is not provided, each lesion must be carefully
interpreted in the clinical context. An alternative for the
TES could be an analysis of the strain-ratio (fat-lesion-
ratio). This method has also shown good performance in
the evaluation of breast lesions [24]. However, we de-
cided to use the TES, as this score was the first classifi-
cation system for elastograms in the literature, there is
the most experience with this score, as the majority of
cases in the literature were analyzed with the TES.
The application of different ultrasound systems
For the examinations, we used two different ultrasound
systems that were available in our breast cancer center.
As the applied elastography modules are based on
similar technologies, we presume that there are no
differences. However, our study was not intended or
empowered to explore differences between the two
ultrasound systems. So far, there are no larger studies
comparing different sonoelastography systems, but
smaller cases series suggest that there is probably no
major influence on the elastographic score [25].
Limitations of the study
The main limitation of our study is that analysis of
elastograms is, to a certain degree, observer-dependent,
as it is based on image interpretation. It should be noted
that conventional breast ultrasound and evaluation of
B-mode images is also observer-dependent and a matter
of subjective interpretation. Therefore, this limitation is
inherent in sonoelastography per se and conventional
B-mode ultrasound as well. So far, computer-aided diag-
nosis has shown little benefit for the analysis of ultra-
sound elasticity images and, in our view, visual
assessment of elastograms by the examiner remains the
gold-standard [26].
Another limitation is the lack of multiple observers
and multiple study sites. All examinations were carried
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and many years’ experience with sonoelastography. To
evaluate the performance under realistic conditions, the
study concept should be repeated with multiple ob-
servers with different levels of experience. The outcome
bias was minimized in our study setting, as the examiner
did not know the final nature of the lesion at the time of
the elastographic assessment. Furthermore, the B-mode
images yielded no additional information, as all lesions
were categorized BI-RADSW-US 3 and appeared prob-
ably benign.
Finally, to prove our concept, we see an imperative
need for a prospective, multicenter trial to fully evaluate
breast sonoelastography in a standard clinical setting.
Furthermore, studies focusing on other risk groups
(i.e. BI-RADSW 4a, 4b and 4c) would be beneficial.
Conclusions
Sonoelastography yields additional diagnostic informa-
tion in the evaluation of BI-RADSW-US 3 lesions of the
breast and enables the examiner to identify a low-risk
group that can be watchfully observed as well as a high-
risk group that should receive immediate biopsy due to
an elevated breast cancer risk.
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